• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

Recent Advances in the Study of 5-Pyrimidinamine, 2-propoxy- (CAS: 1248968-09-3): A Promising Compound in Chemical Biology and Pharmaceutical Research

The chemical compound 5-Pyrimidinamine, 2-propoxy- (CAS: 1248968-09-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic amine, characterized by its pyrimidine backbone and propoxy substitution, has shown potential in various therapeutic applications, including oncology, infectious diseases, and metabolic disorders. Recent studies have focused on elucidating its mechanism of action, optimizing its pharmacokinetic properties, and exploring its efficacy in preclinical models.

One of the key areas of research has been the compound's role as a kinase inhibitor. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is often implicated in cancer and other diseases. Preliminary data suggest that 5-Pyrimidinamine, 2-propoxy- exhibits selective inhibition against specific kinase targets, making it a promising candidate for targeted therapy. Researchers have employed molecular docking studies and in vitro assays to validate its binding affinity and inhibitory potency, with results indicating a high degree of specificity for certain kinase isoforms.

In addition to its kinase inhibitory properties, recent investigations have explored the compound's potential as an antimicrobial agent. Studies have demonstrated its efficacy against a range of bacterial and fungal pathogens, particularly those with resistance to conventional antibiotics. The compound's unique chemical structure appears to disrupt microbial cell wall synthesis and metabolic pathways, offering a novel mechanism of action that could address the growing challenge of antimicrobial resistance.

Another promising avenue of research involves the compound's application in metabolic disorders. Early-stage studies have shown that 5-Pyrimidinamine, 2-propoxy- can modulate key enzymes involved in lipid and glucose metabolism, suggesting potential benefits for conditions such as diabetes and obesity. Animal models have revealed improvements in insulin sensitivity and reductions in hepatic steatosis following treatment with the compound, although further studies are needed to confirm these findings and assess long-term safety.

Despite these encouraging results, challenges remain in the development of 5-Pyrimidinamine, 2-propoxy- as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential off-target effects must be addressed through structural optimization and advanced formulation strategies. Recent efforts have focused on synthesizing derivatives with improved pharmacokinetic profiles and reduced toxicity, leveraging modern medicinal chemistry techniques such as structure-activity relationship (SAR) studies and high-throughput screening.

In conclusion, 5-Pyrimidinamine, 2-propoxy- (CAS: 1248968-09-3) represents a versatile and promising compound with broad applications in chemical biology and pharmaceutical research. Its dual functionality as a kinase inhibitor and antimicrobial agent, coupled with its potential metabolic benefits, underscores its value as a subject of ongoing investigation. Future research should prioritize translational studies to bridge the gap between preclinical findings and clinical applications, ultimately paving the way for its development into a viable therapeutic option.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)